Skip to main content
. 2020 Jun 25;4(8):e10375. doi: 10.1002/jbm4.10375

Figure 2.

Figure 2

Percent change from baseline in areal BMD at the (A) total hip (TH), (B) distal femur metaphysis (DFM), (C) distal femur epiphyses (DFE), and (D) proximal tibia epiphysis (PTE). Percent change from baseline for denosumab versus placebo at the respective time points: * p < 0.05; p < 0.01; ** p < 0.001.